,,ii #aaith ,,congress #ast ,session ,s4 #aied ,,in ,,the ,,senate ,,of ,,the ,,united ,,states ,june #d1 #bjbe ,mr4 ,lee 7for himself1 ,mr4 ,lujn1 ,mr4 ,paul1 and ,ms4 ,hassan7 introduced the following bill2 which was read twice and referred to the ,committee on ,health1 ,education1 ,labor1 and ,pensions ,a ,,bill ,to improve the requirements for making a determination of interchangeability of a biological product and its reference product4 #a4 ,short title ,this ,act may be cited as the ,biosimilar ,red ,tape ,elimination ,act4 #b4 ,biosimilar biological products 7a7 ,in general ,section #cea7k7 of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #bfb7k77 is amended-- 7#a7 in the subsection heading1 by striking or interchangeable2 7#b7 in paragraph 7#b7-- 7,a7 by striking subparagraph 7,b72 7,b7 by redesignating clauses 7ii7 and 7iii7 of subparagraph 7,a7 as subparagraphs 7,b7 and 7,c71 respectively1 and adjusting the margins accordingly2 7,c7 in subparagraph 7,a7-- 7i7 in clause 7i71 by redesignating subclauses 7,i7 through 7,v7 as clauses 7i7 through 7v71 respectively1 and adjusting the margins accordingly2 7ii7 in clause 7i71 as so redesignated by clause 7i7 of this subparagraph1 by redesignating items 7aa7 through 7cc7 as subclauses 7,i7 through 7,,iii71 respectively1 and adjusting the margins accordingly2 and 7iii7 by striking 7,a7 ,in ,general and all that follows through ,an application submitted under this subsection shall include information and inserting the following3 7,a7 ,in general ,an application submitted under this subsection shall include information 2 7,d7 in subparagraph 7,b71 as so redesignated by subparagraph 7,b7 of this paragraph1 by striking clause 7i77,i7 and inserting subparagraph 7,a77i72 and 7,e7 in subparagraph 7,c71 as so redesignated by subparagraph 7,b7 of this paragraph1 by redesignating subclauses 7,i7 through 7,,iii7 as clauses 7i7 through 7iii71 respectively1 and by adjusting the margins accordingly2 7#c7 by amending subparagraph 7,a7 of paragraph 7#c7 to read as follows3 7,a7 the ,secretary determines that the information submitted in the application 7or the supplement7 is sufficient to show that the biological product is biosimilar to the reference product2 and 2 7#d7 by amending paragraph 7#d7 to read as follows3 7#d7 ,interchangeability 7,a7 ,in general ,a biological product licensed under this subsection shall be deemed to be interchangeable with the reference product1 subject to subparagraph 7,b74 7,b7 ,timing of deemed interchangeability 7i7 ,licensure on or after transition date ,a biological product licensed under this subsection on or after the transition date described in subparagraph 7,c7 7referred to in this clause as the applicable biological product7 shall be deemed to be interchangeable with the reference product upon such licensure1 unless the applicable biological product relied on the same reference product as another biological product for which-- 7,i7 licensure under this subsection was in effect on the date of enactment of the ,biosimilar ,red ,tape ,elimination ,act2 and 7,,ii7 a first interchangeable exclusivity period under paragraph 7#f7 7as in effect on the date of enactment of the ,biosimilar ,red ,tape ,elimination ,act7 is in effect on the date of licensure of the applicable biological product1 in which case the applicable biological product shall be deemed interchangeable with the reference product under this paragraph on the date on which the exclusivity period described in subclause 7,,ii7 ends4 7ii7 ,licensure prior to transition date ,a biological product licensed under this subsection prior to the transition date described in subparagraph 7,c7 7referred to in this clause as the applicable biological product7 shall be deemed to be interchangeable with the reference product on such transition date1 unless the applicable biological product relied on the same reference product as another biological product for which-- 7,i7 licensure under this subsection was in effect on the date of enactment of the ,biosimilar ,red ,tape ,elimination ,act2 and 7,,ii7 a first interchangeable exclusivity period under paragraph 7#f7 7as in effect on the date of enactment of the ,biosimilar ,red ,tape ,elimination ,act7 is in effect on the transition date1 in which case the applicable biological product shall be deemed interchangeable with the reference product under this paragraph on the date on which the exclusivity period described in subclause 7,,ii7 ends4 7,c7 ,transition date ,the transition date described in this subparagraph is the date that is #fj days after the date of enactment of the ,biosimilar ,red ,tape ,elimination ,act4 2 7#e7 by amending paragraph 7#f7 to read as follows3 7#f7 ,transition with respect to preserving first interchangeability exclusivity with respect to certain biological products ,with respect to a biological product licensed under this subsection before the date of enactment of the ,biosimilar ,red ,tape ,elimination ,act1 for which there was an unexpired period of first interchangeable exclusivity under this subsection 7as then in effect71 such unexpired exclusivity period shall remain in effect for the duration of such period4 2 and 7#f7 in paragraph 7#h77;,d7-- 7,a7 in clause 7i71 by striking class2 and and inserting class42 7,b7 by striking clause 7ii72 and 7,c7 by striking description of-- and all that follows through criteria that the ,secretary and inserting description of the criteria that the ,secretary4 7b7 ,conforming amendments 7#a7 ,section #cea7;i77#c7 of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #bfb7;i77#c77 is amended by striking that is shown to meet the standards described in subsection 7k77#d7 and inserting licensed under subsection 7k74 7#b7 ,section #ceb;,a of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #bfc-a7 is amended by striking and interchangeable biosimilar biological products each place it appears4 7#c7 ,section #gdd;,g7#ad7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cgi;j-#ea7ad77 is amended by striking 1 including a supplement requesting that the ,secretary determine that the biosimilar biological product meets the standards for interchangeability described in section #cea7k77#d7 of the ,public ,health ,service ,act4 7#d7 ,by amending subsection 7l7 of section #eje;,b of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cee;c7 to read as follows3 7l7 ,biosimilar biological products ,a biological product for which an application is submitted under section #cea7k7 of the ,public ,health ,service ,act shall not be considered to have a new active ingredient for purposes of this section1 unless the application seeks licensure for-- 7#a7 a claimed indication that has been approved for the reference product in a relevant pediatric population or for which there is a deferral of the pediatric assessment under paragraph 7#d7 for the reference product2 and 7#b7 the assessment would not involve the development of a biological product with a strength1 dosage form1 route of administration1 or condition of use that could not be licensed under section #cea7k7 of the ,public ,health ,service ,act4 4 7c7 ,guidance ,the ,secretary shall-- 7#a7 not later than #ah months after the date of enactment of this ,act1 update existing draft and final guidance to reflect the amendments made by this ,act1 including by revising or revoking the guidance document titled ,considerations in ,demonstrating ,interchangeability ,with a ,reference ,product 7,may #bjai7 and ,considerations in ,demonstrating ,interchangeability ,with a ,reference ,product3 ,update 7,june #bjbd72 7#b7 not later than #ah months after the date of enactment of this ,act1 issue or revise guidance on review and approval of biosimilar biological products under section #cea7k7 of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #bfb7k77 relating to the data and information that an applicant is required to submit to support a determination that a biosimilar biological product that is the subject of an application under such section is biosimilar to the reference product 7as defined in section #cea7;i7 of such ,act 7#db ,u4,s4,c4 #bfb7;i7772 and 7#c7 not later than #ah months after the comment period closes on the guidance under paragraphs 7#a7 and 7#b71 issue revised draft or final versions of such guidances4